MedTrace Logo

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

NCT00798304 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2014-11-26

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B vaccine in healthy infants.

Conditions

  • Meningitis, Meningococcal

Interventions

BIOLOGICAL

meningococcal B rLP2086 vaccine

vaccination

BIOLOGICAL

Routine age appropriate childhood vaccines

vaccination

BIOLOGICAL

meningococcal B rLP2086 vaccine

vaccination

BIOLOGICAL

Routine age appropriate childhood vaccines

vaccination

BIOLOGICAL

Routine age appropriate childhood vaccines

vaccination

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
42 Days
Max Age
98 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-06-30
Completion
2009-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00798304 on ClinicalTrials.gov